These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Vermes A; van Der Sijs H; Guchelaar HJ Chemotherapy; 2000; 46(2):86-94. PubMed ID: 10671757 [TBL] [Abstract][Full Text] [Related]
6. Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis. Roberts JA; Udy AA; O'Donoghue S; Briscoe S; Paterson DL; Lipman J Int J Antimicrob Agents; 2009 Oct; 34(4):383-4. PubMed ID: 19540094 [No Abstract] [Full Text] [Related]
7. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. Haberkorn U; Oberdorfer F; Gebert J; Morr I; Haack K; Weber K; Lindauer M; van Kaick G; Schackert HK J Nucl Med; 1996 Jan; 37(1):87-94. PubMed ID: 8544010 [TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Ueda K; Iwahashi M; Nakamori M; Nakamura M; Matsuura I; Yamaue H; Tanimura H Cancer Res; 2001 Aug; 61(16):6158-62. PubMed ID: 11507067 [TBL] [Abstract][Full Text] [Related]
9. [Monitoring of treatment involving 5-fluorocytosine]. Dellamonica P; Fournier JP; Garraffo R; Lapalus P; Bernard E; Chichmanian RM; Marty P; Le Fichoux Y Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):642-5. PubMed ID: 3911161 [TBL] [Abstract][Full Text] [Related]
10. Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. Miller CR; Gustin AN; Buchsbaum DJ; Vickers SM; Manne U; Grizzle WE; Cloud GA; Diasio RB; Johnson MR Anal Biochem; 2002 Feb; 301(2):189-99. PubMed ID: 11814289 [TBL] [Abstract][Full Text] [Related]
11. Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor. Manome Y; Watanabe M; Abe T; Tomita M; Watanabe S; Yokokawa Y; Takahashi Y; Ishii K; Kimura A; Murakami M; Nagata M; Shibata T; Nakamura M; Tanigawa N; Ohno T Anticancer Res; 2001; 21(4A):2265-72. PubMed ID: 11724281 [TBL] [Abstract][Full Text] [Related]
12. Flucytosine therapeutic monitoring: 15 years experience from the UK. Pasqualotto AC; Howard SJ; Moore CB; Denning DW J Antimicrob Chemother; 2007 Apr; 59(4):791-3. PubMed ID: 17339279 [TBL] [Abstract][Full Text] [Related]
13. [Sensitivity of yeasts against 5 fluorocytosine. Comparison of five methods (author's transl)]. Brinkmann F Z Hautkr; 1981 Oct; 56(19):1255-63. PubMed ID: 7032101 [TBL] [Abstract][Full Text] [Related]
14. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Miller CR; Williams CR; Buchsbaum DJ; Gillespie GY Cancer Res; 2002 Feb; 62(3):773-80. PubMed ID: 11830532 [TBL] [Abstract][Full Text] [Related]
15. Laboratory methods for flucytosine (5-fluorocytosine). Report of a Working Group of the British Society for Mycopathology. J Antimicrob Chemother; 1984 Jul; 14(1):1-8. PubMed ID: 6480540 [No Abstract] [Full Text] [Related]
16. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. van der Voort PH; Boerma EC; Yska JP J Antimicrob Chemother; 2007 May; 59(5):952-6. PubMed ID: 17389717 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and the bystander effect in CD::UPRT/5-FC bi-gene therapy of glioma. Shi DZ; Hu WX; Li LX; Chen G; Wei D; Gu PY Chin Med J (Engl); 2009 Jun; 122(11):1267-72. PubMed ID: 19567135 [TBL] [Abstract][Full Text] [Related]
18. Individualization of 5-fluorocytosine therapy. Petersen D; Demertzis S; Freund M; Schumann G; Oellerich M Chemotherapy; 1994; 40(3):149-56. PubMed ID: 8205932 [TBL] [Abstract][Full Text] [Related]
19. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Gillum JG; Johnson M; Lavoie S; Venitz J Pharmacotherapy; 1995; 15(2):251-3. PubMed ID: 7624273 [TBL] [Abstract][Full Text] [Related]